Navigation Links
TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
Date:9/22/2009

d vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Boston Scientific PROMUS(R) and First-Generation TAXUS(R) Express(R) Stents Continue Excellent Performance in SPIRIT III Trial
2. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
3. SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
4. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
5. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
6. TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
7. A consistent decline in heart attack rates following the implementation of smoking bans
8. Drug-eluting stents safe, effective for treatment of chronic total occlusions
9. Researchers find drug-eluting stents safe, effective for PCI in diabetics
10. New type of sirolimus-eluting stent demonstrates superior results
11. Sono-Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... of youth" drug that can delay the effects of aging ... suggests. Seniors received a significant boost to their immune ... pathway linked to aging and immune function, researchers with the ... a version of the drug rapamycin, improved the seniors, immune ...
(Date:12/25/2014)... Viejo, California (PRWEB) December 25, 2014 ... release of ProFire 5k. A fully customizable business presentation ... . , “Adding the ProFire 5k business tool, users ... Said Christina Austin, CEO of Pixel Film Studios. “ProFire ... look and style to add professionalism to a presentation” ...
(Date:12/24/2014)... December 25, 2014 AlignLife of Wauwatosa ... to afford certain items. During the holiday season, AlignLife looks ... over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. ... such joy, knowing that we are able to give kids ... it not been for the generosity of our patients." , ...
(Date:12/24/2014)... 25, 2014 Recently, iFitDress.com, a famous dress ... prom dresses under $150 . All these items are brand ... website has already been updated with the new range of ... ordered so far. All iFitDress.com’s designs are made according to ... using great materials. Every outfit from the company is handpicked ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... to Fund Growth, IRVINE, Calif., Sept. 17 ... announced that it has retained,investment banking firm Empire ... and,lead financing strategies. Assured Pharmacy, Inc. is a ... pain and other,long-term care conditions. "Empire Financial ...
... Symmetry Medical Inc.,(NYSE: SMA ), an independent ... and other medical markets, announced today the launch ... which contains improved,user- friendly features. The ... easy to,find product information and a streamlined log-in ...
... might improve treatment, researchers say , , MONDAY, Sept. 17 ... gene that plays a crucial role in the ability ... The finding that transcription factor AP2C (TFAP2C) controls multiple ... for hormone-responsive breast cancer and may help explain differences ...
... In October the American College of Physicians (ACP) will ... Dr. Harvey Makadon, Dr. Ken Mayer, and Hilary Goldhammer ... Dr. Jennifer Potter of Beth Israel Deaconess Medical Center, ... medical providers about the unique health care needs of ...
... of Warrenton, Virginia announces an innovative twist to ... too familiar with,traveling to food shows where vendors ... winning a sale. Vernon Rhea, Director of Nutrition,and ... long-standing,commitment to individualized patient care to the selection ...
... Debate, WASHINGTON, Sept. 17 The British ... partner,with three Los Angeles area universities to present ... of the National Theatre of Scotland,s,Black Watch, the ... as described by soldiers in Scotland,s legendary Black ...
Cached Medicine News:Health News:Assured Pharmacy Retains Empire Financial Group 2Health News:Assured Pharmacy Retains Empire Financial Group 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:American College of Physicians publishes 'The Fenway Guide to LGBT Health' 2Health News:Fauquier Health System Holds a Food Show with a Twist Long Term Care Patients Hold the Judge's Pen as Vendors Vie for Approval 2Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 2Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 3Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 4Health News:British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues 5
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 23, 2014   Assurex Health, a personalized ... healthcare providers for behavioral health and chronic pain ... million in equity financing from new and existing ... President and Chief Executive Officer. The ... of Assurex Health,s GeneSight ®  products.  ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a ... Phase 3 study required for New Drug Application (NDA) ... 140 patients has greater than 90% power to detect ... to enrol additional patients. QRxPharma anticipates completing analysis of ...
... or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that ... clearance from the U.S. Food and Drug Administration (FDA). ... variant of the Unitract™ 1mL Insulin Syringe for which ... syringes which are primarily used by people with diabetes, ...
Cached Medicine Technology:QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 3Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 2Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 3
The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
... The ADC drugs of abuse tests are highly ... the SAMHSA recommended cut-off as confirmed by GC/MS ... A more specific alternative method (such as GC/MS) ... confirmed result. Professional judgment should be applied to ...
Ovulation test for the rapid detection of LH in urine. Our ovulation tests, designed to accurately detect fertility in a user-friendly presentation, are also available for professional and over-the-c...
... designed for women actively wishing to become pregnant. ... the time of high fertility typically up ... her peak fertility. By doing so, it maximises ... number of test sticks and a hand held ...
Medicine Products: